Artificial intelligence in hepatocellular carcinoma: imaging-based subtyping and prediction of treatment response and prognosis
Abdominal Radiology · 2026
DOI: 10.1007/s00261-026-05520-2 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Abdominal Radiology, 2026. Verfasst von Maria El Homsi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Memorial Sloan Kettering Cancer Center, New York, USA. elhomsim@mskcc.org. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Artificial Intelligence. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 68 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Memorial Sloan Kettering Cancer Center, New York, USA. elhomsim@mskcc.org.
- Southern Radiology Consultants, Baton Rouge, USA.
- Banner - University Medical Center Tucson, Tucson, USA.
- Department of Radiology, University of Colorado Anschutz Medical Campus, University of Colorado, Boulder, USA.
- University of Chicago, Chicago, USA.
- University of North Carolina School of Medicine, Chapel Hill, USA.
Zitieren
APA
El Homsi, M., Sabottke, C., Singh, C., Harmath, C., & Spieler, B. (2026). Artificial intelligence in hepatocellular carcinoma: imaging-based subtyping and prediction of treatment response and prognosis. Abdominal Radiology. https://doi.org/10.1007/s00261-026-05520-2
Vancouver
El Homsi M, Sabottke C, Singh C, Harmath C, Spieler B. Artificial intelligence in hepatocellular carcinoma: imaging-based subtyping and prediction of treatment response and prognosis. Abdominal Radiology. 2026. doi:10.1007/s00261-026-05520-2
BibTeX
@article{ElHomsi2026,
author = {El Homsi, Maria and Sabottke, Carl and Singh, Charanjeet and Harmath, Carla and Spieler, Bradley},
title = {Artificial intelligence in hepatocellular carcinoma: imaging-based subtyping and prediction of treatment response and prognosis},
journal = {Abdominal Radiology},
year = {2026},
doi = {10.1007/s00261-026-05520-2}
}
EUVIMED